Paul P Tak Selected Research

Systemic Lupus Erythematosus (Libman-Sacks Disease)

1/2019	Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
7/2013	Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up.
9/2012	Sustained Rap1 activation in autoantigen-specific T lymphocytes attenuates experimental autoimmune encephalomyelitis.
7/2012	Pathogenesis of spondyloarthritis: autoimmune or autoinflammatory?
1/2012	Signal transduction pathways in chronic inflammatory autoimmune disease: small GTPases.
3/2010	Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Paul P Tak Research Topics

Disease

160	Rheumatoid Arthritis 01/2022 - 01/2002
64	Inflammation (Inflammations) 01/2022 - 02/2002
54	Arthritis (Polyarthritis) 01/2020 - 10/2002
20	Psoriatic Arthritis 01/2022 - 10/2002
17	Experimental Arthritis 01/2016 - 01/2004
13	Synovitis 01/2016 - 08/2006
12	Necrosis 01/2018 - 01/2004
10	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2022 - 01/2004
10	Autoimmune Diseases (Autoimmune Disease) 12/2016 - 01/2009
9	Osteoarthritis 03/2016 - 01/2004
8	Neoplasms (Cancer) 01/2022 - 03/2007
8	Rheumatic Diseases (Rheumatism) 10/2019 - 12/2008
7	Spondylarthritis (Spinal Arthritis) 10/2012 - 06/2006
6	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2019 - 03/2010
6	Infections 12/2016 - 04/2009
5	Joint Diseases (Joint Disease) 12/2017 - 06/2002
3	Pain (Aches) 01/2019 - 01/2010
3	Osteitis 01/2016 - 04/2011
3	Disease Progression 11/2014 - 09/2011
3	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 09/2012 - 01/2010
3	Atherosclerosis 03/2012 - 03/2007
3	Melanoma (Melanoma, Malignant) 01/2012 - 01/2009
2	Genetic Predisposition to Disease (Genetic Predisposition) 01/2019 - 10/2013
2	Injection Site Reaction 01/2018 - 01/2010
2	Erythema 12/2017 - 01/2017
2	Tertiary Lymphoid Structures 07/2015 - 08/2007
2	Overweight 01/2015 - 10/2013

Drug/Important Bio-Agent (IBA)

26	CytokinesIBA 01/2022 - 04/2002
26	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2004
23	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2004
20	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022 - 03/2005
18	Rituximab (Mabthera)FDA Link 10/2019 - 03/2007
17	AutoantibodiesIBA 01/2022 - 07/2008
14	Methotrexate (Mexate)FDA LinkGeneric 01/2022 - 02/2002
12	Anti-Citrullinated Protein AntibodiesIBA 08/2020 - 11/2004
12	Biological ProductsIBA 01/2018 - 04/2007
11	ChemokinesIBA 01/2018 - 01/2004
9	AntibodiesIBA 01/2021 - 11/2004
9	Interleukin-6 (Interleukin 6)IBA 01/2020 - 01/2004
9	LigandsIBA 01/2020 - 07/2008
9	Infliximab (Remicade)FDA Link 08/2011 - 01/2004
8	Pharmaceutical PreparationsIBA 01/2019 - 04/2004
8	Rheumatoid FactorIBA 01/2019 - 11/2005
8	Matrix Metalloproteinases (MMPs)IBA 01/2017 - 06/2006
8	Antirheumatic Agents (DMARD)IBA 03/2016 - 06/2008
6	Adalimumab (Humira)FDA Link 01/2022 - 09/2010
6	Interleukin-17 (Interleukin 17)IBA 01/2022 - 01/2009
6	Monoclonal AntibodiesIBA 01/2018 - 08/2006
6	EnzymesIBA 12/2017 - 01/2008
6	C-Reactive ProteinIBA 12/2017 - 01/2010
5	InterleukinsIBA 01/2022 - 02/2014
5	Immunoglobulin M (IgM)IBA 01/2017 - 08/2011
5	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 01/2015 - 01/2009
5	Interferon-betaIBA 01/2015 - 01/2002
5	Interleukin-10 (Interleukin 10)IBA 01/2014 - 01/2006
4	Peptides (Polypeptides)IBA 01/2019 - 01/2006
4	Tumor Necrosis Factor InhibitorsIBA 01/2019 - 01/2009
4	Histone Deacetylases (Histone Deacetylase)IBA 01/2017 - 01/2008
4	Histone Deacetylase InhibitorsIBA 01/2017 - 03/2010
4	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 12/2016 - 01/2004
4	Phosphotransferases (Kinase)IBA 09/2015 - 05/2006
4	tocilizumab (atlizumab)FDA Link 01/2015 - 05/2011
4	Chemokine ReceptorsIBA 03/2013 - 05/2005
4	Etanercept (Enbrel)FDA Link 01/2013 - 03/2005
4	AntigensIBA 09/2012 - 01/2006
4	Therapeutic UsesIBA 03/2010 - 01/2002
4	NF-kappa B (NF-kB)IBA 06/2009 - 01/2004
3	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 04/2007
3	RNA (Ribonucleic Acid)IBA 01/2021 - 07/2009
3	sirukumabIBA 01/2018 - 01/2017
3	Messenger RNA (mRNA)IBA 01/2018 - 11/2008
3	Toll-Like Receptors (Toll-Like Receptor)IBA 02/2016 - 12/2008
3	Poly I-CIBA 01/2016 - 01/2012
3	CollagenIBA 01/2015 - 04/2010
3	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 10/2014 - 08/2006
3	ImmunosorbentsIBA 10/2014 - 11/2008
3	AngiopoietinsIBA 01/2014 - 08/2012
3	Abatacept (Orencia)FDA Link 08/2013 - 04/2011
3	Immunoglobulins (Immunoglobulin)IBA 06/2013 - 06/2011
3	Alefacept (Amevive)FDA Link 09/2012 - 10/2002
3	GTP Phosphohydrolases (GTPases)IBA 12/2010 - 01/2009
3	Collagen Type II (Type II Collagen)IBA 09/2010 - 01/2009
3	alpha7 Nicotinic Acetylcholine ReceptorIBA 09/2010 - 01/2009
3	HLA-DRB1 Chains (HLA DRB1)IBA 07/2009 - 06/2003
2	Interleukin-1 (Interleukin 1)IBA 01/2019 - 01/2010
2	Prostaglandins AIBA 01/2018 - 05/2011
2	CC ChemokinesIBA 01/2018 - 11/2010
2	Macrophage Colony-Stimulating FactorIBA 12/2016 - 03/2016
2	Colony-Stimulating Factors (Colony Stimulating Factor)IBA 12/2016 - 03/2016
2	GSK1210151AIBA 02/2016 - 11/2014
2	Small Interfering RNA (siRNA)IBA 02/2016 - 03/2010
2	LipopolysaccharidesIBA 02/2016 - 03/2012
2	Interleukin-23 (Interleukin 23)IBA 01/2016 - 06/2012
2	Apolipoprotein A-I (Apolipoprotein A1)IBA 11/2015 - 01/2015
2	Transcription Factors (Transcription Factor)IBA 09/2015 - 09/2015
2	Acetylcholine (Acetylcholine Chloride)FDA Link 01/2015 - 01/2009

Therapy/Procedure

41	Therapeutics 10/2019 - 02/2002
5	Biological Therapy 01/2017 - 06/2011
4	Aftercare (After-Treatment) 09/2012 - 03/2005
2	Immunotherapy 01/2022 - 06/2009